CD37 Amatoxin Antibody Conjugates for Ibrutinib-Resistant B-Cell Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for CD37-based antibodies in cancer therapy are limited in efficacy and do not effectively target cancer cells, and there is a need for agents with improved potency and efficacy profile to overcome ibrutinib resistance in CD37-positive B-cell malignancies.
Innovation Solution
Development of amatoxin-based conjugates comprising CD37-specific antibodies or fragments, linked via non-cleavable or cleavable linkers, to deliver cytotoxic effects on CD37-positive cells, including those resistant to ibrutinib.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CD37-based antibody treatments are used, then treatment is provided for B-cell malignancies, but efficacy is limited and ibrutinib resistance cannot be overcome
Solution Approach 1:
The patent creates composite antibody-drug conjugates by chemically linking amatoxin (a potent cytotoxic agent) to CD37-specific antibodies through specialized linkers. This composite structure combines the target-specific binding capability of the antibody with the high cytotoxic potency of amatoxin, achieving reliable treatment efficacy while overcoming ibrutinib resistance in CD37-positive B-cell malignancies
2Reliability
If amatoxin-based conjugates are developed, then potency and efficacy are improved, but device complexity increases due to conjugate structure
Solution Approach 1:
The patent introduces linker molecules as intermediaries that chemically connect the CD37-specific antibody to the amatoxin payload. These linkers (such as maleimide-based linkers or click chemistry linkers) serve as mediators that enable stable conjugation while maintaining the functional integrity of both components, thereby achieving high potency and efficacy without excessive structural complexity
Solution Approach 2:
The patent optimizes various parameters of the conjugate structure including the linker length, linker chemistry (cleavable vs. non-cleavable), drug-to-antibody ratio, and amatoxin derivative selection. By systematically adjusting these parameters, the patent achieves optimal potency and efficacy while controlling the complexity of the overall conjugate structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amatoxin-based conjugates demonstrate significant cytotoxic effects on CD37-positive cells in vitro and in vivo, overcoming ibrutinib resistance and effectively treating B-cell malignancies such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and other CD37-expressing diseases.
Implementation Method 1
conjugates comprising an amatoxin, a target-binding moiety wherein the target is CD37
Implementation Method 2
amatoxin-based conjugates demonstrate significant cytotoxic effects on CD37-positive cells
Data Source
AI summary
A conjugate contains an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking the amatoxin and said CD37-binding moiety, and the conjugate is prepared in a synthesis method. A pharmaceutical composition contains the conjugate for use in the treatment of immune cell-, particularly B-cell and/or lymphoma associated diseases and/or malignancies.